Although the Covid-19 pandemic persisted throughout the year, the healthcare industry continued to fulfill its duty based on experiences of last year. While going all out to develop Covid-19 treatments and vaccines, the industry tried to graft new technologies, including AI, to promote the sector's development. In the process, the industry revealed problems requiring correction, such as manipulating raw materials and impurities caught in antihypertensive drugs. Still, the sector continued to improve itself in keeping with the changing global healthcare industry amid the Covid-19 crisis. Korea Biomedical Review has compiled the five biggest industry stories in 2021.

As Margaretta Colangelo, Partner at Deep Knowledge Ventures, mentions in her recent article'Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials. Moreover, 75% of newly approved drugs are unable to cover the cost of development and some analysts predict that ROI in pharmaceutical R&D may hit zero by 2020.' If we accept that this prediction has some good chances to become reality, then we should see the AI as the Deus ex Machina in the field of pharmaceutical R&D to keep a business alive, but also give the invaluable hope of choice to some patients. In this race for life, some firms set the pace trying to test their limits in uncharted waters. Deep Knowledge Analytics, a subsidiary of Deep Knowledge Ventures, an investment fund focused on DeepTech, separates the companies that are solely dedicated to core scientific R&D out of a total of 1000 AI Healthcare companies globally. According to DKA'The barriers to entry in the AI Healthcare industry are lower than for AI in drug discovery and these companies can achieve real results with much less funding and fewer highly specialized employees.'

As Margaretta Colangelo, Partner at Deep Knowledge Ventures, mentions in her recent article'Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials. Moreover, 75% of newly approved drugs are unable to cover the cost of development and some analysts predict that ROI in pharmaceutical R&D may hit zero by 2020.' If we accept that this prediction has some good chances to become reality, then we should see the AI as the Deus ex Machina in the field of pharmaceutical R&D to keep a business alive, but also give the invaluable hope of choice to some patients. In this race for life, some firms set the pace trying to test their limits in uncharted waters. Deep Knowledge Analytics, a subsidiary of Deep Knowledge Ventures, an investment fund focused on DeepTech, separates the companies that are solely dedicated to core scientific R&D out of a total of 1000 AI Healthcare companies globally. According to DKA'The barriers to entry in the AI Healthcare industry are lower than for AI in drug discovery and these companies can achieve real results with much less funding and fewer highly specialized employees.'

As Margaretta Colangelo, Partner at Deep Knowledge Ventures, mentions in her recent article'Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials. Moreover, 75% of newly approved drugs are unable to cover the cost of development and some analysts predict that ROI in pharmaceutical R&D may hit zero by 2020.' If we accept that this prediction has some good chances to become reality, then we should see the AI as the Deus ex Machina in the field of pharmaceutical R&D to keep a business alive, but also give the invaluable hope of choice to some patients. In this race for life, some firms set the pace trying to test their limits in uncharted waters. Deep Knowledge Analytics, a subsidiary of Deep Knowledge Ventures, an investment fund focused on DeepTech, separates the companies that are solely dedicated to core scientific R&D out of a total of 1000 AI Healthcare companies globally. According to DKA'The barriers to entry in the AI Healthcare industry are lower than for AI in drug discovery and these companies can achieve real results with much less funding and fewer highly specialized employees.'